SCHEMBL4975356

SCHEMBL4975356

CCN(CC)c1ccc2cc[nH]c2n1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.38
AXL P30530 1/20 0.37
NUDT1 P36639 1/20 0.37
BRD4 O60885 1/20 0.36
TERT O14746 1/20 0.35
MAOA P21397 2/20 0.35
KDM4E B2RXH2 1/20 0.33
KMT2A Q03164 1/20 0.33
APP P05067 1/20 0.32
ELANE P08246 1/20 0.32
TAAR1 Q96RJ0 1/20 0.32
CNR1 P21554 1/20 0.32
BCHE P06276 1/20 0.31
LMNA P02545 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C19 P33261 1/20 0.31
MCHR1 Q99705 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14639241 0.76 ELANE (0.42) GBA1MAOAKDM4EKMT2AELANE
SCHEMBL4167148 0.71 AXL (0.41) AXLNUDT1BRD4MAOAAPP
SCHEMBL417520 0.70 JAK3 (0.47) BRD4
SCHEMBL4975460 0.69 TGFBR1 (0.39) AXLNUDT1BRD4
SCHEMBL27797376 0.68 AXL (0.38) AXLNUDT1BRD4APP
SCHEMBL417409 0.68 APP (0.42) AXLNUDT1BRD4APPELANE
SCHEMBL343400 0.67 ADORA2A (0.57) AXLNUDT1BRD4KDM4EKMT2A
SCHEMBL415512 0.67 JAK3 (0.55)
SCHEMBL411599 0.67 AXL (0.46) AXLNUDT1BRD4KDM4EAPP
SCHEMBL5925823 0.67 AXL (0.37) AXLNUDT1BRD4APPCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8247556-B2 Method for preparing 6-substituted-7-aza-indoles AMGEN INC. (US) 2012-08-21 US claimed
US-8247556-B2 Method for preparing 6-substituted-7-aza-indoles AMGEN INC. (US) 2012-08-21 US disclosed
EP-1971604-B1 PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES AMGEN INC (US) 2012-08-01 EP disclosed
EP-1971604-A2 PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES Amgen Inc. (US) 2008-09-24 EP disclosed
US-20070185171-A1 Compounds and methods of use AMGEN INC. 2007-08-09 US disclosed
WO-2007048070-A2 PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES AMGEN INC. (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185171-A1 Compounds and methods of use VHL, PGF, PTGIS GBA1 45/4885AXL 1711/4885NUDT1 346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.